Results 141 to 150 of about 15,400,316 (399)

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Berberine induces caspase-independent cell death in colon tumor cells through activation of apoptosis-inducing factor [PDF]

, 2011
Berberine, an isoquinoline alkaloid derived from plants, is a traditional medicine for treating bacterial diarrhea and intestinal parasite infections. Although berberine has recently been shown to suppress growth of several tumor cell lines, information ...
D. Brent Polk, Fang Yan, Hamwei Cao, Keith Wilson, Lihong Wang, Liping Liu, Rupesh Chaturvedi, Tianhui Hu, Yan Shi   +8 more
core   +1 more source

Hypoxic Cell Waves around Necrotic Cores in Glioblastoma: A Biomathematical Model and its Therapeutic Implications

, 2012
Glioblastoma is a rapidly evolving high-grade astrocytoma that is distinguished pathologically from lower grade gliomas by the presence of necrosis and microvascular hiperplasia.
Calvo, Gabriel F., Martínez-González, Alicia, Pérez-García, Víctor M., Romasanta, Luis A. Pérez   +3 more
core   +1 more source

Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma

, 2021
Stefan Alig, Charles Macaulay, David M. Kurtz, Ulrich Dührsen, Andreas Hüttmann, Christine Hanoun, Michael C. Jin, Brian J. Sworder, Andrea Garofalo, Mohammad Shahrokh Esfahani, Barzin Y. Nabet, Joanne Soo, Florian Scherer, Alexander Craig, Olivier Casasnovas, Jason R. Westin, Gianluca Gaïdano, Davide Rossi, Mark Roschewski, Wyndham H. Wilson, Michel Meignan, Maximilian Diehn, Ash A. Alizadeh   +22 more
openalex   +2 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function [PDF]

, 2005
Alfonso Catalano, Paola Caprari, Simona Moretti, Monica Faronato, Luca Tamagnone, Antonio Domenico Procopio   +5 more
openalex   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs

Frontiers in Oncology
IntroductionDetection of PIK3CA mutations in primary tumors and liquid biopsy samples is of increasing importance for treatment decisions and therapy resistance in many types of cancer. The aim of the present study was to directly compare the efficacy of
Stavroula Smilkou, Loukas Kaklamanis, Ioanna Balgouranidou, Helena Linardou, Alkistis Maria Papatheodoridi, Flora Zagouri, Evangelia Razis, Stylianos Kakolyris, Amanda Psyrri, Christos Papadimitriou, Athina Markou, Evi Lianidou   +11 more
doaj   +1 more source